Dae Gon Ha
Stock Analyst at Stifel
(2.43)
# 2,490
Out of 5,143 analysts
54
Total ratings
36.36%
Success rate
5.3%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $92 → $98 | $107.48 | -8.82% | 5 | Dec 16, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.40 | +270.37% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.11 | +42.18% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $39.16 | +88.97% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $8.58 | -65.03% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $13.58 | +371.28% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $266.90 | -17.57% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $22.75 | +458.24% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $4.25 | +1,029.41% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.83 | +369.97% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $1.92 | +264.58% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.28 | +405.84% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $98.65 | -74.66% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.36 | +11.42% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $26.92 | +958.69% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.51 | +1,224.50% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.63 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $22.13 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.61 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.88 | +1,260.70% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $22.27 | +2,100.27% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Dec 16, 2025
Maintains: Buy
Price Target: $92 → $98
Current: $107.48
Upside: -8.82%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.40
Upside: +270.37%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.11
Upside: +42.18%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $39.16
Upside: +88.97%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $8.58
Upside: -65.03%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $13.58
Upside: +371.28%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $266.90
Upside: -17.57%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $22.75
Upside: +458.24%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $4.25
Upside: +1,029.41%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.83
Upside: +369.97%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.92
Upside: +264.58%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.28
Upside: +405.84%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $98.65
Upside: -74.66%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.36
Upside: +11.42%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $26.92
Upside: +958.69%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.51
Upside: +1,224.50%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.63
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $22.13
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.61
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.88
Upside: +1,260.70%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $22.27
Upside: +2,100.27%